دورية أكاديمية
أعرض في EDS

Humoral and cellular immune responses to CoronaVac up to one year after vaccination.

التفاصيل البيبلوغرافية
العنوان: Humoral and cellular immune responses to CoronaVac up to one year after vaccination.
المؤلفون: Costa PR; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Correia CA; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Marmorato MP; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Dias JZC; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Thomazella MV; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Cabral da Silva A; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., de Oliveira ACS; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Gusmão AF; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Ferrari L; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil., Freitas AC; Department of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of São Paulo, São Paulo, Brazil., Patiño EG; Center for Clinical Trials and Pharmacovigilance Butantan Institute, São Paulo, Brazil., Grifoni A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States., Weiskopf D; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States., Sette A; Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, San Diego, CA, United States.; Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, San Diego, CA, United States., Scharf R; PATH, Washington, DC, United States., Kallás EG; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.; Department of Infectious and Parasitic Diseases, Clinicas Hospital, School of Medicine, University of São Paulo, São Paulo, Brazil., Silveira CGT; Medical Investigation Laboratory 60 (LIM-60), School of Medicine, University of São Paulo, São Paulo, Brazil.
المصدر: Frontiers in immunology [Front Immunol] 2022 Oct 21; Vol. 13, pp. 1032411. Date of Electronic Publication: 2022 Oct 21 (Print Publication: 2022).
نوع المنشور: Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Lausanne : Frontiers Research Foundation]
مواضيع طبية MeSH: COVID-19* , COVID-19 Vaccines*, Humans ; Antibodies, Viral ; Cytokines ; Immunity, Cellular ; Immunoglobulin G ; SARS-CoV-2 ; Vaccination
مستخلص: Coronavac is a widely used SARS-CoV-2 inactivated vaccine, but its long-term immune response assessment is still lacking. We evaluated SARS-CoV-2-specific immune responses, including T cell activation markers, antigen-specific cytokine production and antibody response following vaccination in 53 adult and elderly individuals participating in a phase 3 clinical trial. Activated follicular helper T (Tfh), non-Tfh and memory CD4 + T cells were detected in almost all subjects early after the first vaccine dose. Activated memory CD4 + T cells were predominantly of central and effector memory T cell phenotypes and were sustained for at least 6 months. We also detected a balanced Th1-, Th2- and Th17/Th22-type cytokine production that was associated with response over time, together with particular cytokine profile linked to poor responses in older vaccinees. SARS-CoV-2-specific IgG levels peaked 14 days after the second dose and were mostly stable over one year. CoronaVac was able to induce a potent and durable antiviral antigen-specific cellular response and the cytokine profiles related to the response over time and impacted by the senescence were defined.
Competing Interests: Employees of Fundação Butantan and Instituto Butantan participated in the clinical trial design and data collection. Author AS is a consultant for Gritstone Bio, Flow Pharma, ImmunoScape, Moderna, AstraZeneca, Avalia, Fortress, Repertoire, Gilead, Gerson Lehrman Group, RiverVest, MedaCorp, and Guggenheim. The La Jolla Institute (LJI) has filed for patent protection for various aspects of T cell epitope and vaccine design work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2022 Costa, Correia, Marmorato, Dias, Thomazella, Cabral da Silva, de Oliveira, Gusmão, Ferrari, Freitas, Patiño, Grifoni, Weiskopf, Sette, Scharf, Kallás and Silveira.)
التعليقات: Update of: medRxiv. 2022 Jul 07;:. (PMID: 35821982)
References: Nat Med. 2020 Sep;26(9):1428-1434. (PMID: 32661393)
Trials. 2020 Oct 15;21(1):853. (PMID: 33059771)
Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
Immunol Cell Biol. 2014 Jan;92(1):72-9. (PMID: 24217812)
Lancet. 2021 Jul 17;398(10296):213-222. (PMID: 34246358)
Immunity. 2021 Sep 14;54(9):2133-2142.e3. (PMID: 34453880)
PLoS One. 2011 Feb 09;6(2):e16982. (PMID: 21347390)
Sci Immunol. 2021 Oct 22;6(64):eabk0894. (PMID: 34519539)
Arch Gerontol Geriatr. 2014 Sep-Oct;59(2):234-9. (PMID: 24856646)
Cell Rep Med. 2020 Sep 22;1(6):100081. (PMID: 32839763)
Nature. 2022 Jan;601(7893):311. (PMID: 35027748)
BMJ. 2021 Aug 20;374:n2015. (PMID: 34417194)
Nature. 2020 Aug;584(7821):457-462. (PMID: 32668444)
Cell. 2021 Feb 18;184(4):861-880. (PMID: 33497610)
Sci Immunol. 2021 Dec 24;6(66):eabl5344. (PMID: 34726470)
Immunity. 2014 Oct 16;41(4):529-42. (PMID: 25367570)
Biomed Res Int. 2015;2015:521957. (PMID: 26583116)
Front Immunol. 2018 Sep 19;9:2093. (PMID: 30283442)
Immunol Rev. 2022 Sep;310(1):27-46. (PMID: 35733376)
Cell. 2020 Jun 25;181(7):1489-1501.e15. (PMID: 32473127)
Sci Rep. 2021 Nov 8;11(1):21601. (PMID: 34750399)
Science. 2020 Jul 3;369(6499):77-81. (PMID: 32376603)
Immunity. 2011 Dec 23;35(6):919-31. (PMID: 22195747)
Immunity. 2016 Jun 21;44(6):1379-91. (PMID: 27287409)
Nat Immunol. 2004 Feb;5(2):133-9. (PMID: 14749784)
Front Immunol. 2020 Oct 27;11:579220. (PMID: 33193377)
Science. 2021 Feb 5;371(6529):. (PMID: 33408181)
Cell. 2022 Jul 7;185(14):2434-2451.e17. (PMID: 35764089)
Sci Immunol. 2021 Nov 19;6(65):eabl9105. (PMID: 34618554)
J Infect Dis. 2022 Apr 1;225(7):1141-1150. (PMID: 34888672)
Vaccines (Basel). 2021 Oct 12;9(10):. (PMID: 34696277)
Lancet Infect Dis. 2021 Dec;21(12):1645-1653. (PMID: 34197764)
Immunity. 2020 Jun 16;52(6):971-977.e3. (PMID: 32413330)
Cell Host Microbe. 2021 Jul 14;29(7):1076-1092. (PMID: 34237248)
Clin Infect Dis. 2022 Aug 24;75(1):e792-e804. (PMID: 34537835)
Immunology. 2022 Jul;166(3):327-340. (PMID: 35396852)
Cell. 2022 Feb 17;185(4):603-613.e15. (PMID: 35026152)
J Leukoc Biol. 2017 Oct;102(4):977-988. (PMID: 28733462)
Front Immunol. 2022 Apr 22;13:869990. (PMID: 35529867)
معلومات مُعتمدة: 75N93019C00065 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: CoronaVac; cellular response; humoral response; immune memory; vaccination
المشرفين على المادة: 0 (Antibodies, Viral)
0 (COVID-19 Vaccines)
0 (Cytokines)
0 (Immunoglobulin G)
تواريخ الأحداث: Date Created: 20221107 Date Completed: 20221110 Latest Revision: 20221222
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9634255
DOI: 10.3389/fimmu.2022.1032411
PMID: 36341425
قاعدة البيانات: MEDLINE
الوصف
تدمد:1664-3224
DOI:10.3389/fimmu.2022.1032411